Xiaojia Niu
Key Laboratory For Molecular Enzymology And Engineering, 2699 Qianjin Street
Changchun, China
Changchun, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer.
Journal: Cancer chemotherapy and pharmacology
Published: July 24, 2020
Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.
Journal: Signal transduction and targeted therapy
Published: January 05, 2017
Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells.
Journal: Journal of medicinal chemistry
Published: August 10, 2016
Synergistic anti-leukemic interactions between ABT-199 and panobinostat in acute myeloid leukemia ex vivo.
Journal: American journal of translational research
Published: March 22, 2016
Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 21, 2015
Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer.
Journal: Cancer letters
Published: December 06, 2013
Expression and purification of recombinant NRL-Hsp90α and Cdc37-CRL proteins for in vitro Hsp90/Cdc37 inhibitors screening.
Journal: Protein expression and purification
Published: May 15, 2013
Showing 1-10 of 10
Last Updated: 09/26/2026